

JFW



Atty. Dkt. No. 039363-0703

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Ryan Bremer et al.  
Title: CRYSTAL STRUCTURE OF  
PIM-1 KINASE  
Appl. No.: 10/664,421  
Filing Date: 09/16/2003  
Examiner:  
Art Unit:

<p><b>CERTIFICATE OF MAILING</b> I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.</p> <p><u>DIANE GARCIA</u> (Printed Name)</p> <p><u>Diane Garcia</u> (Signature)</p> <p><u>9-22-04</u> (Date of Deposit)</p>
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Mail Stop Amendment-IDS  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document, except as noted below, is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The USPTO has waived the requirement under 37 CFR 1.98(a)(2)(i) to submit copies of U.S. patents and U.S. patent application publications when citing and submitting an Information Disclosure Statements in a patent application filed after June 30, 2003 and in an international application that has entered the national stage under 37 USC §371 after June 30, 2003. Accordingly, copies of these types of documents are not being supplied in connection with this application. Reference is being made to Pre-OG Notice from Office of Patent Legal Administration dated July 25, 2003, *Information Disclosure Statements May Be Filed Without*

*Copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003.*

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

#### **TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

#### **RELEVANCE OF EACH DOCUMENT**

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even

entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit  
Account No. 50-0872.

Respectfully submitted,


Date 21 Sept. 2004

By Wesley B. Ames

FOLEY & LARDNER LLP  
Customer Number: 30542  
Telephone: (858) 847-6714  
Facsimile: (858) 792-6773

Wesley B. Ames  
Attorney for Applicant  
Registration No. 40,893

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 26

## **Complete if Known**

Application Number	10/664,421
Filing Date	09/16/2003
First Named Inventor	Ryan BREMER
Group Art Unit	
Examiner Name	
Attorney Docket Number	039363-0703

## **U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	A1	4,150,949		Smith	04-24-1979	
	A2	4,568,649		Bertoglio-Matte	02-04-1986	
	A3	4,626,513		Burton et al.	12-02-1986	
	A4	5,143,854		Pirrung et al.	09-01-1992	
	A5	5,426,039		Wallace et al.	06-20-1995	
	A6	5,434,049		Okano et al.	07-18-1995	
	A7	5,449,614		Danos et al.	09-12-1995	
	A8	5,474,935		Chatterjee et al.	12-12-1995	
	A9	5,516,775		Zimmermann et al.	05-14-1996	
	A10	5,521,184		Zimmermann	05-28-1996	
	A11	5,543,520		Zimmermann	08-06-1996	
	A12	5,556,752		Lockhart et al.	09-17-1996	
	A13	5,580,859		Felgner et al.	12-03-1996	
	A14	5,620,981		Blanklet et al.	04-15-1997	
	A15	5,631,236		Woo et al.	05-20-1997	
	A16	5,632,957		Heller et al.	05-27-1997	
	A17	5,658,775		Gilboa	08-19-1997	
	A18	5,700,637		Southern	12-23-1997	
	A19	5,721,118		Scheffler	02-24-1998	
	A20	5,733,913		Blankley et al.	03-31-1998	
	A21	5,733,914		Blankley et al.	03-31-1998	
	A22	5,744,305		Fodor et al.	04-28-1998	
	A23	5,747,276		Hoch et al.	05-05-1998	
	A24	5,763,198		Hirth et al.	06-09-1998	
	A25	5,770,456		Holmes	06-23-1998	
	A26	5,800,992		Fodor et al.	09-01-1998	
	A27	5,807,522		Brown et al.	09-15-1998	
	A28	5,830,645		Pinkel et al.	11-03-1998	
	A29	5,840,485		Lebl et al.	11-24-1998	
	A30	5,856,174		Lipshutz et al.	01-05-1999	
	A31	5,877,007		Housey	02-02-1999	
	A32	5,945,422		Doherty et al.	08-31-1999	
	A33	5,959,098		Goldberg et al.	09-28-1999	
	A34	5,965,452		Kovacs	10-12-1999	
	A35	6,013,440		Lipshultz et al.	01-11-2000	
	A36	6,022,963		McGall et al.	02-08-2000	
	A37	6,025,155		Hadlaczky et al.	02-15-2000	
	A38	6,045,996		Cronin et al.	04-04-2000	

 Examiner  
Signature

 Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				<b>Application Number</b>	10/664,421
				<b>Filing Date</b>	09/16/2003
				<b>First Named Inventor</b>	Ryan BREMER
				<b>Group Art Unit</b>	
				<b>Examiner Name</b>	
<b>Sheet</b>	2	<b>of</b>	26	<b>Attorney Docket Number</b>	039363-0703

**U.S. PATENT DOCUMENTS**

		U.S. Patent Document			
	A39	6,048,695		Bradley et al.	04-11-2000
	A40	6,054,270		Southern	04-25-2000
	A41	6,090,912		Lebl et al.	07-18-2000
	A42	6,096,718		Weitzman et al.	08-01-2000
	A43	6,107,478		Pedersen et al.	08-22-2000
	A44	6,110,456		During	08-29-2000
	A45	6,110,458		Freeman et al.	08-29-2000
	A46	6,113,913		Brough et al.	09-05-2000
	A47	6,117,681		Salmons et al.	09-12-2000
	A48	6,178,384		Kolossvary	01-23-2001
	A49	6,243,980		Bronstein et al.	06-12-2001
	A50	6,258,606		Kovacs	07-10-2001
	A51	6,261,776		Pirung et al.	07-17-2001
	A52	6,277,489		Abbott et al.	08-21-2001
	A53	6,277,628		Johann et al.	08-21-2001
	A54	6,288,234		Griffin	09-11-2001
	A55	6,294,330		Michnick et al.	09-25-2001

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	A56	WO	95/09847		Ciba-Geigy AG	04-13-1995		
	A57	WO	96/17958		The Regents of the University of California	06-13-1996		
	A58	WO	96/18738		Sugen, Inc.	06-20-1996		
	A59	WO	97/46313		Array Technologies	12-11-1997		
	A60	WO	99/09217		Hyseq, Inc.	02-25-1999		
	A61	WO	99/51773		Phylos, Inc.	10-14-1999		
	A62	EP	0154734		Immunex Corporation	08-29-1990		

<b>Examiner Signature</b>	<b>Date Considered</b>
---------------------------	------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/664,421
		Filing Date	09/16/2003
		First Named Inventor	Ryan BREMER
		Group Art Unit	
Examiner Name			
Sheet	3	of	26
		Attorney Docket Number	039363-0703

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A63	AARONSON, "Growth Factors and Cancer," <i>Science</i> . 254:1146-1153 (1991)	
	A64	ALFTHAN, "Surface Plasmon Resonance Biosensors as a Tool in Antibody Engineering," <i>Biosensors &amp; Bioelectronics</i> 13:653-663 (1998)	
	A65	AL-OBEIDI, "Peptide and Peptidomimetic Libraries – Molecular Diversity and Drug Design," <i>Mol Biotechnol</i> 9(3):205-223 (1998)	
	A66	AMERSDORFER and Marks, "Phage Libraries for Generation of Anti-Botulinum scFv Antibodies," <i>Methods in Molecular Biology</i> 145:219-240 (2001)	
	A67	AMSON <i>et al.</i> , "The Human Proto-Oncogene Product P33pim is Expressed During Fetal Hematopoiesis and in Diverse Leukemias," <i>Proceedings of the National Academy of Sciences</i> 86(22):8857-8861 (1989)	
	A68	BAGSHAW and HARRIS, "Measurement of Ligand Binding to Proteins," <i>Spectrophotometry and Spectrofluorometry: A Practical Approach</i> 4:91-114 (1987)	
	A69	BARTLETT <i>et al.</i> , "CAVEAT: A Program to facilitate the structure-derived design of biologically active molecules." In <i>Molecular Recognition: Chemical and Biological Problems. The Proceedings of an International Symposium, University of Exeter, April 1989, Royal Society of Chemistry, Cambridge</i> 182-196 (1989)	
	A70	BAYTEL, <i>et al.</i> , "The Human <i>Pim-2</i> Proto-oncogene and its Testicular Expression," <i>Biochimica et Biophysica Acta</i> 1442: 274-285 (1998)	
	A71	BELL, "Spectroscopy In Biochemistry," 1:155-194 (1981)	
	A72	BELLIS <i>et al.</i> , "Characterization of Tyrosine Phosphorylation of Paxillin <i>in Vitro</i> by Focal Adhesion Kinase," <i>J Biol Chem</i> 270:17437-17441 (1995)	
	A73	BLUNDELL <i>et al.</i> , "Knowledge-Based Protein Modeling and Design," <i>Eur. J. Biochem.</i> 172:513 (1988)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/664,421		
		Filing Date	09/16/2003		
		First Named Inventor	Ryan BREMER		
		Group Art Unit			
Examiner Name					
Sheet	4	of	26	Attorney Docket Number	039363-0703

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A74	BÖHM, "On the Use of LUDI to Search the Fine Chemicals Directory for Ligands of Proteins of Known Three-Dimensional Structure," <i>J. Comp. Aided Molec. Design</i> 8:623 (1994)	
	A75	BOLGER and SHERMAN, "Computer Modeling of Combining Site Structure of Anti-hapten Monoclonal Antibodies," <i>Methods Enz.</i> 203:21-45 (1991)	
	A76	BOWTELL, "Options Available – From Start to Finish – For Obtaining Expression Data by Microarray," <i>Nature Genetics Supp.</i> 21:25-32 (1999)	
	A77	BRENNER <i>et al.</i> , "Encoded Combinatorial Chemistry," <i>Proc. Natl. Acad. Sci. USA</i> , 89:5381-5383 (1992)	
	A78	BROWN and BIRNBAUMER, "Ionic Channels and Their Regulation by G Protein Subunits," <i>Ann. Rev. Physiol.</i> 52:197-213 (1990)	
	A79	BRÜNGER, "Free R value: A Novel Statistical Quantity for Assessing the Accuracy of Crystal Structures," <i>Nature</i> 355:472-475 (1992)	
	A80	BUCHSCHER and PANGANIBAN, "Human Immunodeficiency Virus Vectors for Inducible Expression of Foreign Genes," <i>J. Virol.</i> 66:2731-2739 (1992)	
	A81	CAPON, <i>et al.</i> , "Designing CD4 Immunoadhesins for AIDS Therapy," <i>Nature</i> 377:525-531 (1989)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/664,421
		Filing Date	09/16/2003
		First Named Inventor	Ryan BREMER
		Group Art Unit	
Examiner Name			
Sheet	5	of	26
		Attorney Docket Number	039363-0703

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A82	CARELL <i>et al.</i> , "New Promise in Combinatorial Chemistry: Synthesis, Characterization, and Screening of Small-Molecule Libraries Solution," <i>Chem. Biol.</i> 3:171-183 (1995)	
	A83	CHABALA, "Solid-Phase Combinatorial Chemistry and Novel Tagging Methods for Identifying Leads," <i>Curr Opin Biotechnol</i> 6(6):633-639 (1995)	
	A84	CHECOVICH <i>et al.</i> , "Fluorescence Polarization – a New Tool for Cell and Molecular Biology," <i>Nature</i> 375:254-256 (1995)	
	A85	CHEN <i>et al.</i> "Pim Serine/Threonine Kinases Regulate the Stability of Socs-1 Protein," <i>Proceedings of the National Academy of Sciences of the United States of America</i> 99(4):2175-2180 (2002)	
	A86	CLARK <i>et al.</i> , "PRO-LIGAND: An Approach to De Novo Molecular Design. 1. Application to the Design of Organic Molecules," <i>J. Comp. Aided Molec. Design</i> 9:13 (1995)	
	A87	COBB <i>et al.</i> , "Stable Association of pp60 <sup>src</sup> and pp59 <sup>lyn</sup> with the Focal Adhesion-Associated Protein Tyrosine Kinase, pp125 <sup>FAK</sup> ," <i>Mol. Cell. Biol.</i> 14(1):147-155 (1994)	
	A88	COE and STORER, "Solution-phase combinatorial chemistry." <i>Molecular Diversity</i> , 4:1-38, 1999.	
	A89	COLLIUOD, "Oriented and Covalent Immobilization of Target Molecules to Solid Supports: Synthesis and Application of a Light-Activatable and Thiol-Reactive Cross-Linking Reagent," <i>Bioconjugate Chem.</i> 4:528-536 (1993)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/664,421		
		Filing Date	09/16/2003		
		First Named Inventor	Ryan BREMER		
		Group Art Unit			
Examiner Name					
Sheet	6	of	26	Attorney Docket Number	039363-0703

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A90	COLMAN, "Structure-Based Drug Design," <i>Current Opinion in Struc. Biol.</i> 4:868 (1994)	
	A91	COTRAN et al., "Healing and Repair," Robbins Pathologic Basis of Disease, 4 <sup>th</sup> Edition, p. 75, (1989)	
	A92	CREIGHTON, "An Empirical Approach to Protein Conformation Stability and Flexibility," <i>Biopolymers</i> 22(1):49-58 (1983)	
	A93	CUYPERS, et al., "Murine Leukemia Virus-Induced T-Cell Lymphomagenesis: Integration of Provirus in a Distinct Chromosomal Region," <i>Cell</i> , Vol. 37, pp. 141-150, (1984)	
	A94	CWIRLA et al., "Peptides on Phage: A Vast Library of Peptides for Identifying Ligands," <i>Biochemistry</i> 87:6378-6382 (1990)	
	A95	DANDLIKER, et al., "Equilibrium and Kinetic Inhibition Assays Based Upon Fluorescence Polarization," <i>Methods in Enzymology</i> 74:3-28 (1981)	
	A96	DIKIC et al., "A Role For Pyk2 and Src in Linking G-Protein-Coupled Receptors with MAP Kinase Activation," <i>Nature</i> 383:547-550 (1996)	
	A97	DOBELI, "Recombinant Fusion Proteins for the Industrial Production of Disulfide Bridge Containing Peptides: Purification, Oxidation Without Concatamer Formation, and Selective Cleavage," <i>Protein Expr. Purif.</i> 12:404-414 (1998)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/664,421
				Filing Date	09/16/2003
				First Named Inventor	Ryan BREMER
				Group Art Unit	
Examiner Name					
Sheet	7	of	26	Attorney Docket Number	039363-0703

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A98	DOLLE and NELSON, "Comprehensive Survey of Combinatorial Library Synthesis: 1998," <i>J Comb Chem</i> 1(4):235-282 (1999)	
	A99	DOLPHIN, "G Protein Modulation of Calcium Currents in Neurons," <i>Ann. Rev. Physiol.</i> 52:243-255 (1990)	
	A100	DOMEN, <i>et al.</i> , "Pim-1 Levels Determine the Size of Early B Lymphoid Compartments in Bone Marrow," <i>The Journal of Experimental Medicine</i> 178(5)1665-1673 (1993)	
	A101	DUONG <i>et al.</i> , "PYK2 in Osteoclasts is an Adhesion Kinase, Localized in the Sealing Zone, Activated by Ligation of $\alpha_v\beta_3$ Integrin, and Phosphorylated by Src Kinase," <i>J Clin Invest.</i> 102:881-892 (1998)	
	A102	EICHMANN <i>et al.</i> , "Developmental Expression of Pim Kinases Suggests Functions Also Outside of the Hematopoietic System," <i>Oncogene</i> 19:1215-1224 (2000)	
	A103	ELISEEV and LEHN, "Dynamic Combinatorial Chemistry: Evolutionary Formation and Screening of Molecular Libraries," <i>Current Topics in Microbiology &amp; Immunology</i> 243:159-172 (1999)	
	A104	ENJALBAL <i>et al.</i> , "Mass Spectrometry in Combinatorial Chemistry," <i>Mass Spectrometry Reviews.</i> 19:139-161 (2000)	
	A105	FENG <i>et al.</i> , "Stable in Vivo Gene Transduction Via a Novel Adenoviral/Retroviral Chimeric Vector," <i>Nature Biotechnology</i> 15:866-870 (1997)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/664,421
				Filing Date	09/16/2003
				First Named Inventor	Ryan BREMER
				Group Art Unit	
Examiner Name					
Sheet	8	of	26	Attorney Docket Number	039363-0703

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	A106	FISCHER and SCHONBRUNN, "The Bombesin Receptor is Coupled to a Guanine Nucleotide-Binding Protein Which is Insensitive to Pertussis and Cholera Toxins," <i>J. Biol. Chem.</i> , 263(6):2808-2816 (1988)		
	A107	FIVASH <i>et al.</i> , "BIAcore for Macromolecular Interaction," <i>Current Opinion in Biotechnology</i> 9:97-101 (1998)		
	A108	FREIDINGER RM., "Nonpeptidic Ligands for Peptide and Protein Receptors," <i>Current Opinion in Chemical Biology</i> 3:395-406 (1999)		
	A109	FRUCHT, <i>et al.</i> , "Characterization of Functional Receptors for Gastrointestinal Hormones on Human Colon Cancer Cells," <i>Cancer Research</i> , 52:1114-1122 (1992)		
	A110	GALLOP <i>et al.</i> , "Applications of Combinatorial Technologies to Drug Discovery. 1. Background and Peptide Combinatorial Libraries," <i>J. Med. Chem.</i> , 37:1233-1251 (1994)		
	A111	GILMAN, A., "G Proteins: Transducers of Receptor-Generated Signals," <i>Ann. Rev. Biochem.</i> 56:615-649 (1987)		
	A112	GOODFORD, P., "A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules," <i>J. Med. Chem.</i> 28:849-857 (1985)		
	A113	GOODSELL and OLSON, "Automated Docking of Substrates to Proteins by Simulated Annealing," <i>Proteins: Structure, Function, and Genetics</i> 8:195-202 (1990)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/664,421
				Filing Date	09/16/2003
				First Named Inventor	Ryan BREMER
				Group Art Unit	
				Examiner Name	
Sheet	9	of	26	Attorney Docket Number	039363-0703

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A114	GORDON <i>et al.</i> , "Applications of Combinatorial Technologies to Drug Discovery. 2. Combinatorial Organic Synthesis, Library Screening Strategies, and Future Directions," <i>J. Med. Chem.</i> , 37:1385-1401 (1994)	
	A115	GORDON and FORD, "Detection of Peroxides and Their Removal," <i>The Chemist's Companion: A Handbook Of Practical Data, Techniques, And References</i> , John Wiley and Sons, p. 437 (1972)	
	A116	GRAM H., "Phage Display in Proteolysis and Signal Transduction," <i>Combinatorial Chemistry &amp; High Throughput Screening</i> 2:19-28 (1999)	
	A117	GRAVERT and JANDA, "Synthesis on Soluble Polymers: New Reactions and the Construction of Small Molecules," <i>Curr. Opin. Chem. Biol.</i> 1(1):107-13 (1997)	
	A118	GREER, J., "Model Structure for the Inflammatory Protein C5a," <i>Science</i> 228:1055-1060 (1985)	
	A119	GUIDA, C., "Software for Structure-Based Drug Design," <i>Current Opinion in Struc. Biol.</i> 4:777-781 (1994)	
	A120	GUMBINER, B., "Proteins Associated with the Cytoplasmic Surface of Adhesion Molecules," <i>Neuron</i> , 11:551-564 (1993)	
	A121	HAFNER <i>et al.</i> , "Isothermal Amplification and Multimerization of DNA by <i>Bst</i> DNA Polymerase," <i>Biotechniques</i> 30:852-856 (2001)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/664,421
		Filing Date	09/16/2003
		First Named Inventor	Ryan BREMER
		Group Art Unit	
Examiner Name			
Sheet	10	of	26
		Attorney Docket Number	039363-0703

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A122	HANDS, <i>et al.</i> , "A Convenient Method for the Preparation of 5-, 6- and 7-Azaindoles and Their Derivatives," <i>Synthesis</i> , pp. 877-882 (1996).	
	A123	HANSELMAN <i>et al.</i> , "A cDNA-Dependant Scintillation Proximity Assay for Quantifying Apolipoprotein A-1," <i>J. Lipid Res.</i> 38:2365-2373 (1997)	
	A124	HARTMANN, H., "Moleküldesign Bei Fluoreszenzfarbstoffen," <i>Chimia</i> , 48:512-514 (1994)	
	A125	HAUCK, <i>et al.</i> , "Focal Adhesion Kinase Functions as a Receptor-Proximal Signaling Component Required for Directed Cell Migration," <i>Immunol Res.</i> 21:293-303 (2000)	
	A126	HEIM and TSIEN, "Engineering Green Fluorescent Protein for Improved Brightness, Longer Wavelengths and Fluorescence Resonance Energy Transfer," <i>Curr. Biol.</i> 6:178-182 (1996)	
	A127	HENDRICKSON <i>et al.</i> , "Phase Determination from Multiwavelength Anomalous Diffraction Measurements," <i>Methods of Enzymology</i> 276:494-523 (1997)	
	A128	HENDRICKSON <i>et al.</i> , "Selenomethionyl Proteins Produced for Analysis by Multiwavelength Anomalous Diffraction (MAD): a Vehicle for Direct Determination of Three-Dimensional Structure," <i>The EMBO Journal</i> 9(5):1665-1672 (1990)	
	A129	HILDEBRAND, <i>et al.</i> , "Identification of Sequences Required for the Efficient Localization of the Focal Adhesion Kinase, p125 <sup>FAK</sup> , to Cellular Focal Adhesions," <i>J. Cell Biol.</i> 123(4):993-1005 (1993)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/664,421
				Filing Date	09/16/2003
				First Named Inventor	Ryan BREMER
				Group Art Unit	
Examiner Name					
Sheet	11	of	26	Attorney Docket Number	039363-0703

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A130	HILDEBRAND, <i>et al.</i> , "An SH3 Domain-Containing GTPase-Activating Protein for Rho and Cdc42 Associates with Focal Adhesion Kinase," <i>Mol Cell Biol</i> , 16:3169-3178 (1996)	
	A131	HILLE, B., "G Protein-Coupled Mechanisms and Nervous Signaling," <i>Neuron</i> , 9:187-195 (1992)	
	A132	HOUGHTEN <i>et al.</i> , "Generation and Use of Synthetic Peptide Combinatorial Libraries for Basic Research and Drug Discovery," <i>Nature</i> , 354:84-86 (1991)	
	A133	HOUGHTEN, R., "Peptide Libraries: Criteria and Trends," <i>Trends Genet.</i> , 9:235-239 (1993)	
	A134	HOUGHTON, "Parallel Array and Mixture-Based Synthetic Combinatorial Chemistry: Tools for the Next Millennium," <i>Annu Rev Pharmacol Toxicol</i> 40:273-82 (2000)	
	A135	HUANG, <i>et al.</i> , "Tyrosine Kinase-Dependant Suppression of a Potassium Channel by the G Protein-Coupled m1 Muscarinic Acetylcholine Receptor," <i>Cell</i> , 75:1145-1156 (1993)	
	A136	HUGHES-JONES <i>et al.</i> , "Synthesis of Rh Fv Phage-Antibodies Using VH and VL Germline Genes," <i>British Journal of Haematology</i> 105:811-816 (1999)	
	A137	HYNES, R., "Integrins: Bidirectional, Allosteric Signaling Machines," <i>Cell</i> , 110:673-687 (2002)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/664,421
				Filing Date	09/16/2003
				First Named Inventor	Ryan BREMER
				Group Art Unit	
Examiner Name					
Sheet	12	of	26	Attorney Docket Number	039363-0703

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	A138	IWANE, <i>et al.</i> , "Myosin Subfragment-1 is Fully Equipped with Factors Essential for Motor Function," <i>Biophys. Biochem. Res. Comm.</i> 230:76-80 (1997)		
	A139	JOHANN, <i>et al.</i> , "GLVR1, a Receptor for Gibbon Ape Leukemia Virus, is Homologous to a Phosphate Permease of <i>Neurospora Crassa</i> and is Expressed at High Levels in the Brain and Thymus," <i>J. Virol.</i> 66:1635-1640 (1992)		
	A140	JOHNSTON, M., "Gene Chips: Array of Hope for Understanding Gene Regulation," <i>Curr. Biol.</i> 8:R171-R174 (1998)		
	A141	JONES, T., "Interactive Computer Graphics: FRODO," <i>Methods in Enzymology</i> 115:157-171 (1985)		
	A142	JOSEPH-MCCARTHY, D., "Computational Approaches to Structure-Based Ligand Design," <i>Pharmacology &amp; Therapeutics</i> 84:179-191 (1999)		
	A143	KAHL <i>et al.</i> , "A Multiple-Approach Scintillation Proximity Assay to Measure the Association Between Ras and Raf," <i>Anal. Biochem.</i> 243:282-283 (1996)		
	A144	KERN and HAMPTON, "Direct Hybridization of Large-Insert Genomic Clones on High-Density Gridded cDNA Filter Arrays," <i>Biotechniques</i> 23:120-124 (1997)		
	A145	KIM H. and KAHN, M., "A Merger of Rational Drug Design and Combinatorial Chemistry: Development and Application of Peptide Secondary Structure Mimetics," <i>Combinatorial Chemistry &amp; High Throughput Screening</i> 3:167-183 (2000)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/664,421
				Filing Date	09/16/2003
				First Named Inventor	Ryan BREMER
				Group Art Unit	
Examiner Name					
Sheet	13	of	26	Attorney Docket Number	039363-0703

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	A146	KIRKPATRICK, <i>et al.</i> , "Structure-Based Drug Design: Combinatorial Chemistry and Molecular Modeling," <i>Combinatorial Chemistry &amp; High Throughput Screening</i> 2:211-221 (1999)		
	A147	KLINE <i>et al.</i> , "Studies by <sup>1</sup> H Nuclear Magnetic Resonance and Distance Geometry of the Solution Conformation of the x-Amylase Inhibitor Tendamistat," <i>J. Mol. Biol.</i> 189:377-382 (1986)		
	A148	KNIGHTON <i>et al.</i> , "Structural Basis of the Intrasteric Regulation of Myosin Light Chain Kinases," <i>Science</i> 258:130-135 (1992)		
	A149	KOIKE <i>et al.</i> , "Identification of Heterochromatin Protein 1 (HP1) as a Phosphorylation Target by Pim-1 Kinase and the Effect of Phosphorylation on the Transcriptional Repression Function of HP1," <i>FEBS Letters</i> , 476:17-21 (2000)		
	A150	KOLASKAR and TONGAONKAR, "A Semi-Empirical Method for Prediction of Antigenic Determinants on Protein Antigens," <i>FEBBS Lett.</i> 276(1-2):172-174 (1990)		
	A151	KONIETZKO <i>et al.</i> , "Pim Kinase Expression is Induced by LTP Stimulation and Required for the Consolidation of Enduring LTP," <i>The EMBO Journal</i> 18:3359-3369 (1999)		
	A152	KROLL, <i>et al.</i> , "A Multifunctional Prokaryotic Protein Expression System: Overproduction, Affinity Purification, and Selective Detection," <i>DNA Cell. Biol.</i> 12:441-453 (1993)		
	A153	KUNDU <i>et al.</i> , "Combinatorial Chemistry: Polymer Supported Synthesis of Peptide and Non-Peptide Libraries," <i>Progress in Drug Research</i> 53:89-156 (1999)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Complete if Known</b>	
		<b>Application Number</b>	10/664,421
(use as many sheets as necessary)		<b>Filing Date</b>	09/16/2003
		<b>First Named Inventor</b>	Ryan BREMER
		<b>Group Art Unit</b>	
<b>Examiner Name</b>			
<b>Attorney Docket Number</b>	039363-0703		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A154	KUNKEL, T., "Rapid and Efficient Site-Specific Mutagenesis Without Phenotypic Selection," <i>Proc. Natl. Acad. Sci.</i> 82:488-492 (1985)	
	A155	KUNTZ, <i>et al.</i> , "Structure-Based Molecular Design," <i>Acc. Chem. Res.</i> 27:117 (1994)	
	A156	KUNTZ <i>et al.</i> , "A Geometric Approach to Macromolecule-Ligand Interactions," <i>J. Mol. Biol.</i> 162:269 (1982)	
	A157	LAIRD, <i>et al.</i> , "In Vivo Analysis of Pim-1 Deficiency," <i>Nucleic Acids Research</i> 21(20):4750-4755 (1993)	
	A158	LAKKAKORPI, <i>et al.</i> , "Stable Association of PYK2 and p130 <sup>Cas</sup> in Osteoclasts and Their Co-Localization in the Sealing Zone," <i>J Biol Chem</i> , 274:4900-4907 (1999)	
	A159	LAM <i>et al.</i> , "A New Type of Synthetic Peptide Library for Identifying Ligand-Binding Activity," <i>Nature</i> , 354:82-84 (1991)	
	A160	LEBL <i>et al.</i> , "One-Bead-One-Structure," <i>Biopolymers (Peptide Science)</i> 37:177-198 (1995)	
	A161	LEV, <i>et al.</i> , "Protein Tyrosine Kinase PYK2 Involved in Ca <sup>2+</sup> -Induced Regulation of Ion Channel and MAP Kinase Functions," <i>Nature</i> 376:737-745 (1995)	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/664,421
		Filing Date	09/16/2003
		First Named Inventor	Ryan BREMER
		Group Art Unit	
Examiner Name			
Sheet	15	of	26
		Attorney Docket Number	039363-0703

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A162	LI and EARP, "Paxillin is Tyrosine-Phosphorylated by and Preferentially Associates With the Calcium-Dependent Tyrosine Kinase in Rat Liver Epithelial Cells," <i>J Biol Chem</i> , 272:14341-14348 (1997)	
	A163	LIANG <i>et al.</i> , "Ubiquitous Expression and Cell Cycle Regulation of the Protein Kinase PIM-1," <i>Archives of Biochemistry and Biophysics</i> 33(2):259-265 (1996)	
	A164	LILLY <i>et al.</i> , "The PIM-1 Serine Kinase Prolongs Survival and Inhibits Apoptosis-related Mitochondrial Dysfunction in Part Through a <i>bcl-2</i> -dependent Pathway," <i>Oncogene</i> 18:4022-4031 (1999)	
	A165	LIPAROTO and CIARDELLI, "Biosensor Analysis of the Interleukin-2 Receptor Complex," <i>Journal of Molecular Recognition</i> 12:316-321 (1999)	
	A166	LIPINSKI <i>et al.</i> , "Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings," <i>Advanced Drug Delivery Reviews</i> 23:3-25 (1997)	
	A167	LIPSCHULTZ <i>et al.</i> , "Experimental Design for Analysis of Complex Kinetics Using Surface Plasmon Resonance," <i>Methods</i> 20(3):310-318 (2000)	
	A168	LU, <i>et al.</i> , "Oriented Immobilization of Fab' Fragments on Silica Surfaces," <i>Anal. Chem.</i> 67:83-87 (1995)	
	A169	MADDEN <i>et al.</i> , "Synthetic Combinatorial Libraries: Views on Techniques and Their Application," <i>Perspectives in Drug Discovery and Design</i> 2:269-282 (1995)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/664,421		
		Filing Date	09/16/2003		
		First Named Inventor	Ryan BREMER		
		Group Art Unit			
Examiner Name					
Sheet	16	of	26	Attorney Docket Number	039363-0703

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A170	MALMBORG and BORREBAECK, "BIAcore as a Tool in Antibody Engineering," <i>Journal of Immunological Methods</i> 183:7-13 (1995)	
	A171	MALMQVIST <i>et al.</i> , "Biomolecular Interaction Analysis: Affinity Biosensor Technologies for Functional Analysis of Proteins," <i>Current Opinion in Chemical Biology</i> 1:378-383 (1997)	
	A172	MALMQVIST, M., "BIACORE: An Affinity Biosensor System for Characterization of Biomolecular Interactions," <i>Biochemical Society Transactions</i> 27:335-340 (1999)	
	A173	MARKIEWICZ <i>et al.</i> , "Synthetic Oligonucleotide Combinatorial Libraries and Their Applications," <i>Farmaco</i> 55:174-7 (2000)	
	A174	MARTIN, Y., "Computer-Assisted Rational Drug Design," <i>Methods Enz.</i> 203:587-613 (1991)	
	A175	McCALL, <i>et al.</i> , "Characterization of Anti-Mouse Fc Gamma RII Single-Chain Fv Fragments Derived From Human Phage Display Libraries," <i>Immunotechnology</i> 4:71-87 (1998)	
	A176	McPHERSON, A., "Current Approaches to Macromolecular Crystallization," <i>Eur. J. Biochem.</i> 189:1-23 (1990)	
	A177	MCSHAN <i>et al.</i> , "Csk Homologous Kinase Associates with RAFTK/Pyk2 in Breast Cancer Cells and Negatively Regulates its Activation and Breast Cancer Cell Migration," <i>Internat. J. Oncology</i> 21:197-205 (2002)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/664,421
				Filing Date	09/16/2003
				First Named Inventor	Ryan BREMER
				Group Art Unit	
Examiner Name					
Sheet	17	of	26	Attorney Docket Number	039363-0703

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	A178	MEEKER <i>et al.</i> , "Cloning and Characterization of the Human PIM-1 Gene: A Putative Oncogene Related to the Protein Kinases," <i>Journal of Cellular Biochemistry</i> 35:105-112 (1987)		
	A179	MEEKER <i>et al.</i> , "Characterization of the Human PIM-1 Gene: A Putative Proto-Oncogene Coding for a Tissue Specific Member of the Protein Kinase Family," <i>Oncogene Research</i> 1:87-101 (1987)		
	A180	MENG <i>et al.</i> , "Automated Docking With Grid-Based Energy Evaluation," <i>J. Comput. Chem.</i> 13:505-524 (1992)		
	A181	MEROUR and JOSEPH, "Synthesis and Reactivity of 7-Azaindoles (1 <i>H</i> -Pyrrolo [2,3- <i>b</i> ] pyridine)," <i>Current Organic Chemistry</i> 5:471-506 (2001)		
	A182	MERRITT, J., "Solution Phase Combinatorial Chemistry," <i>Comb Chem High Throughput Screen</i> 1(2):57-72 (1998)		
	A183	MIKOVITS <i>et al.</i> , "Potential Cellular Signatures of Viral Infections in Human Hematopoietic Cells," <i>Disease Makers</i> 17:173-178 (2001)		
	A184	MILLER <i>et al.</i> , "FLOG: A System to Select 'Quasi-Flexible' Ligands Complementary to a Receptor of Known Three-Dimensional Structure," <i>J. Comp. Aided Molec. Design</i> 8:153 (1994)		
	A185	MIRANKER and KARPLUS, "Functionality Maps of Binding Sites: A Multiple Copy Simultaneous Search Method," <i>Proteins: Structure, Function, and Genetics</i> 11:29-34 (1991)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/664,421		
		Filing Date	09/16/2003		
		First Named Inventor	Ryan BREMER		
		Group Art Unit			
Examiner Name					
Sheet	18	of	26	Attorney Docket Number	039363-0703

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A186	MITRA <i>et al.</i> , "Fluorescence Resonance Energy Transfer Between Blue-Emitting and Red-Shifted Excitation Derivatives of the Green Fluorescent Protein," <i>Gene</i> 173:13-17 (1996)	
	A187	MOCHIZUKI <i>et al.</i> , "Physical and Functional Interactions Between Pim-1 Kinase and Cdc25A Phosphatase," <i>The Journal of Biological Chemistry</i> 274:8659-18666 (1999)	
	A188	NAGAR <i>et al.</i> , "Crystal Structures of the Kinase Domain of c-Abl in Complex with the Small Molecular Inhibitors PD173955 and Imatinib (STI-571)," <i>Cancer Research</i> 62:4236-4243 (2002)	
	A189	NAGARAJAN <i>et al.</i> , "Localization of the Human Pim Oncogene (PIM) to a Region of Chromosome 6 Involved in Translocations in Acute Leukemias," <i>Proceedings of the National Academy of Sciences of the United States of America</i> 83(8):2556-2560 (1986)	
	A190	NAVAZA, J., "AMoRe: An Automated Package for Molecular Replacement," <i>Acta Crystallogr.</i> A50:157-163 (1994)	
	A191	NEIDLE and JENKINS, "Molecular Modeling to Study DNA Interaction by Anti-Tumor Drugs," <i>Methods Enz.</i> 203:433-458 (1991)	
	A192	NG, <i>et al.</i> , "Engineering Protein-Lipid Interactions: Targeting of Histidine-Tagged Proteins to Metal-Chelating Lipid Monolayers," <i>Langmuir</i> 11:4048-4055 (1995)	
	A193	NICHOLLS <i>et al.</i> , "Protein Folding and Association: Insights From the Interfacial and Thermodynamic Properties of Hydrocarbons," <i>Proteins</i> 11:281-296 (1991)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/664,421		
		Filing Date	09/16/2003		
		First Named Inventor	Ryan BREMER		
		Group Art Unit			
Examiner Name					
Sheet	19	of	26	Attorney Docket Number	039363-0703

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A194	NICHOLS <i>et al.</i> , "Development of a Scintillation Proximity Assay for Peroxisome Proliferator-Activated Receptor $\gamma$ Ligand Binding Domain," <i>Anal. Biochem.</i> 257:112-119 (1998)	
	A195	O'SHANNESSY and WINZOR, "Interpretation of Deviations from Pseudo-First-Order Kinetic Behavior in the Characterization of Ligand Binding by Biosensor Technology," <i>Analytical Biochemistry</i> . 236:275-283 (1996)	
	A196	O'SHANNESSY, D., "Determination of Kinetic Rate and Equilibrium Binding Constants for Macromolecular Interactions: a Critique of the Surface Plasmon Resonance Literature," <i>Current Opinions in Biotechnology</i> . 5:65-71 (1994)	
	A197	OKADA, <i>et al.</i> , "Gene Therapy Against an Experimental Glioma Using Adeno-Associated Virus Vectors," <i>Gene Ther.</i> 3:957-964 (1996)	
	A198	OTWINOWSKI, "Maximum Likelihood refinement of heavy atom parameters." Daresbury, United Kingdom, 80-86 (1991)	
	A199	OWICKI <i>et al.</i> , "Application of Fluorescence Polarization Assays in High-Throughput Screening," <i>Genetic Engineering News</i> 17:27 (1997)	
	A200	PARKER <i>et al.</i> , "Development of High Throughput Screening Assays Using Fluorescence Polarization: Nuclear Receptor-Ligand-Binding and Kinase/Phosphatase Assays," <i>J Biomol Screen</i> 5:77-88 (2000)	
	A201	PERRIN, D., "Nucleic Acids for Recognition and Catalysis: Landmarks, Limitations, and Looking to the Future," <i>Combinatorial Chemistry &amp; High Throughput Screening</i> 3:243-269 (2000)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/664,421
				Filing Date	09/16/2003
				First Named Inventor	Ryan BREMER
				Group Art Unit	
Examiner Name					
Sheet	20	of	26	Attorney Docket Number	039363-0703

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A202	PFLUGRATH <i>et al.</i> , "Crystal Structure Determination, Refinement and the Molecular Model of the x-Amylase Inhibitor Hoe-467A," <i>J. Mol. Biol.</i> 189:383-386 (1986)	
	A203	PLUNKETT and ELLMAN, "A Silicon-Based Linker for Traceless Solid-Phase Synthesis," <i>J. Org. Chem.</i> 60:6006-6007 (1995)	
	A204	POLTE and HANKS, "Interaction Between Focal Adhesion Kinase and Crk-Associated Tyrosine Kinase Substrate p130 <sup>Cas</sup> ," <i>Proc Natl Acad Sci U.S.A.</i> , 92:10678-10682 (1995)	
	A205	POUL, <i>et al.</i> , "Selection of Tumor-Specific Internalizing Human Antibodies from Phage Libraries," <i>Journal of Molecular Biology</i> 301:1149-1161 (2000)	
	A206	PRICE <i>et al.</i> ; "Summary Report on the ISOBM TD-4 Workshop: Analysis of 56 Monoclonal Antibodies Against the MUC1 Mucin," <i>Tumour Biology</i> 19(1):1-20 (1998)	
	A207	RAINIO <i>et al.</i> , "Transcriptional Activity of NFATc1 is Enhanced by the Pim-1 Kinase," <i>Cutting Edge, The Journal of Immunology</i> 1524-1527 (2001)	
	A208	RIDLEY and HALL, "Signal Transduction Pathways Regulating Rho-Mediated Stress Fibre Formation: Requirement For a Tyrosine Kinase," <i>The EMBO Journal</i> 13(11):2600-2610 (1994)	
	A209	ROBERTS <i>et al.</i> , "Generation of an Antibody With Enhanced Affinity and Specificity For Its Antigen by Protein Engineering," <i>Nature</i> 328:731-734 (1987)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/664,421
				Filing Date	09/16/2003
				First Named Inventor	Ryan BREMER
				Group Art Unit	
Examiner Name					
Sheet	21	of	26	Attorney Docket Number	039363-0703

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A210	RODRIGUEZ-PENA, <i>et al.</i> , "Rapid Dephosphorylation of A Mr 80000 Protein, a Specific Substrate of Protein Kinase C Upon Removal of Phorbol Esters, Bombesin and Vasopressin," <i>Biochemical and Biophysical Research Communication</i> 140(1):379-385 (1986)	
	A211	ROSENFELD, M., "Human Artificial Chromosomes Get Real," <i>Nat. Genet.</i> 15:333-335 (1997)	
	A212	SAIKI, R., "Amplification of Genomic DNA," <i>PCR Protocols</i> 13-20 (1990)	
	A213	SAMBROOK <i>et al.</i> , "Introduction of Recombinant Vectors into Mammalian Cells," <i>Molecular Cloning</i> 2 <sup>nd</sup> Ed., 16.30-16.37 (1989)	
	A214	SARIS <i>et al.</i> , "The <i>pim-1</i> Oncogene Encodes Two Related Protein-Serine/Threonine Kinases by Alternative Initiation at AUG and CUG," <i>The EMBO Journal</i> 10(3):655-664 (1991)	
	A215	SASAKI <i>et al.</i> , "Cloning and Characterization of Cell Adhesion Kinase $\beta$ , a Novel Protein-Tyrosine Kinase of the Focal Adhesion Kinase Subfamily," <i>J Biol Chem.</i> 270:21206-21219 (1995)	
	A216	SCHALLER <i>et al.</i> , "Autonomous Expression of a Noncatalytic Domain of the Focal Adhesion-Associated Protein Tyrosine Kinase pp125 <sup>FAK</sup> ," <i>Mol. Cell. Biol.</i> 13(2):785-791 (1993)	
	A217	SCHALLER, <i>et al.</i> , "pp125 <sup>FAK</sup> , a Structurally Distinctive Protein-Tyrosine Kinase Associated with Focal Adhesions," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 89:5192-5196 (1992)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/664,421		
		Filing Date	09/16/2003		
		First Named Inventor	Ryan BREMER		
		Group Art Unit			
Examiner Name					
Sheet	22	of	26	Attorney Docket Number	039363-0703

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A218	SCHLAEPFER <i>et al.</i> , "Signaling Through Focal Adhesion Kinase," <i>Prog in Biophys Mol Biol</i> , 71:435-478 (1999)	
	A219	SCHLESSINGER, J., "Signal Transduction by Allosteric Receptor Oligomerization," <i>Trends Biochem. Sci.</i> , 13:443-47 (1988)	
	A220	SCHNEIDER <i>et al.</i> , "Functional Purification of a Bacterial ATP-Binding Cassette Transporter Protein (MalK) From the Cytoplasmic Fraction of an Overproducing Strain," <i>Protein Expr. Purif.</i> 6435:10 (1995)	
	A221	SCHREY, <i>et al.</i> , "Bombesin and Glucocorticoids Stimulate Human Breast Cancer Cells to Produce Endothelin, a Paracrine Mitogen for Breast Stromal Cells," <i>Cancer Research</i> 52:1786-1790 (1992)	
	A222	SCHUHMANN, <i>et al.</i> , "Immobilization of Enzymes on Langmuir-Blodgett Films Via a Membrane-Bound Receptor. Possible Applications for Amperometric Biosensors," <i>Adv. Mater.</i> 3:388-391 (1991)	
	A223	SCHUMMER, <i>et al.</i> , "Inexpensive Handheld Device For the Construction of High-Density Nucleic Acid Arrays," <i>Biotechniques</i> 23:1087-1092 (1997)	
	A224	SCHWEIZER and HINDSGAUL, "Combinatorial Synthesis of Carbohydrates," <i>Curr Opin Chem Biol</i> 3(3):291-298 (1999)	
	A225	SELVIN <i>et al.</i> , "Fluorescence Resonance Energy Transfer," <i>Meth. Enzymol.</i> 246:300-345 (1995)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/664,421		
		Filing Date	09/16/2003		
		First Named Inventor	Ryan BREMER		
		Group Art Unit			
Examiner Name					
Sheet	23	of	26	Attorney Docket Number	039363-0703

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A226	SHATTIL <i>et al.</i> , "Tyrosine Phosphorylation of pp125 <sup>FAK</sup> in Platelets Requires Coordinated Signaling Through Integrin and Agonist Receptors," <i>J. Biol. Chem.</i> 269(20):14738-14745 (1994)	
	A227	SHEETS <i>et al.</i> , "Efficient Construction of a Large Nonimmune Phage Antibody Library: The Production of High-Affinity Human Single-Chain Antibodies to Protein Antigens" (published erratum) <i>Proc Natl Acad Sci USA</i> 1999 96:795 (1998)	
	A228	SHIROGANE <i>et al.</i> , "Synergistic Roles for Pim-1 and c-Myc in STAT3-Mediated Cell Cycle Progression and Antiapoptosis," <i>Immunity</i> 11:709-719 (1999)	
	A229	SIEGEL <i>et al.</i> , "Mass Spectral Analysis of a Protein Complex Using Single-Chain Antibodies Selected on a Peptide Target: Applications to Functional Genomics," <i>Journal of Molecular Biology</i> 302:285-93 (2000)	
	A230	SIGAL <i>et al.</i> , "A Self-Assembled Monolayer for the Binding and Study of Histidine-Tagged Proteins by Surface Plasmon Resonance," <i>Anal. Chem.</i> 68:490-497 (1996)	
	A231	SMITH, <i>et al.</i> , "Necklace-Coded Polymer-Supported Combinatorial Synthesis of 2-Arylamino benzimidazoles," <i>J. Comb. Chem.</i> 1:368-370 (1999)	
	A232	SOLINAS-TOLDO <i>et al.</i> , "Matrix -Based Comparative Genomic Hybridization: Biochips to Screen for Genomic Imbalances," <i>Genes, Chromosomes &amp; Cancer</i> 20:399-407 (1997)	
	A233	TAYLOR <i>et al.</i> , "The Rapid Generation of Oligonucleotide-Directed Mutations at High Frequency Using Phosphorothioate-Modified DNA," <i>Nucl. Acids Res.</i> 13:8764-8785 (1985)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/664,421
				Filing Date	09/16/2003
				First Named Inventor	Ryan BREMER
				Group Art Unit	
Examiner Name					
Sheet	24	of	26	Attorney Docket Number	039363-0703

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A234	TEMPLE <i>et al.</i> , "Microarray Analysis of Eosinophils Reveals a Number of Candidate Survival and Spoptosis Genes," <i>Am. J. Respir. Cell Mol. Biol.</i> 25:425-433 (2001)	
	A235	ULLRICH and SCHLESSINGER, "Signal Transduction by Receptors With Tyrosine Kinase Activity," <i>Cell</i> , 61:203-212 (1990)	
	A236	UNDENFRIEND <i>et al.</i> , "Scintillation Proximity Assay: A Sensitive and Continuous Isotopic Method for Monitoring Ligand/Receptor and Antigen/Antibody Interactions," <i>Anal. Biochem.</i> 161:494-500 (1987)	
	A237	VAN DER HOUVEN <i>et al.</i> , "X-Ray-Induced Lymphomagenesis in Eμ-pim-1 Transgenic Mice: An Investigation of the Co-Operating Molecular Events," <i>Carcinogenesis</i> 19(5):847-853 (1998)	
	A238	VAN LOHUIZEN <i>et al.</i> , "Predisposition to Lymphomagenesis in pim-1 Transgenic Mice: Cooperation with c-myc and N-myc in Murine Leukemia Virus-Induced Tumors," <i>Cell</i> 56:673-682 (1989)	
	A239	VAN REGENMORTEL, "Use of Biosensors to Characterize Recombinant Proteins," <i>Developments in Biological Standardization</i> 83:143-51 (1994)	
	A240	VELY <i>et al.</i> , "BIAcore <sup>®</sup> Analysis to Test Phosphopeptide-SH2 Domain Interactions," <i>Methods in Molecular Biology</i> 121:313-21 (2000)	
	A241	VERBEEK <i>et al.</i> , "Mice Bearing the Eμ-myc and Eμ-pim-1 Transgenes Develop Pre-B-Cell Leukemia Prenatally," <i>Molecular and Cellular Biology</i> 11(2):1176-1179 (1991)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/664,421
				Filing Date	09/16/2003
				First Named Inventor	Ryan BREMER
				Group Art Unit	
Examiner Name					
Sheet	25	of	26	Attorney Docket Number	039363-0703

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	A242	WANG <i>et al.</i> , "Pim-1 Negatively Regulates the Activity of PTP-U2S Phosphatase and Influences Terminal Differentiation and Apoptosis of Monoblastoid Leukemia Cells," <i>Archives of Biochemistry and Biophysics</i> , 390(1):9-18 (2001)		
	A243	WEBER, P., "Physical Principles of Protein Crystallization," <i>Adv. Protein Chem.</i> 41:1-36 (1991)		
	A244	WESSJOHANN, "Synthesis of Natural-Product-Based Compound Libraries," <i>Curr Opin Chem Biol</i> 4(3):303-9 (2000)		
	A245	WHARAM <i>et al.</i> , "Specific Detection of DNA and RNA Targets Using a Novel Isothermal Nucleic Acid Amplification Assay Based on the Formation of a Three-Way Junction Structure," <i>Nucleic Acids Res.</i> 29(11):1-8 (2001)		
	A246	WILK-BLASZCZAK <i>et al.</i> , "Bradykinin Modulates Potassium and Calcium Currents in Neuroblastoma Hybrid Cells Via Different Pertussis Toxin-Insensitive Pathways," <i>Neuron</i> 12:109-116 (1994)		
	A247	WILLIAMS <i>et al.</i> , "Dissection of Extracellular Human Interferon $\gamma$ Receptor $\alpha$ -Chain Into Two Immunoglobulin-Like Domains. Production in an Escherichia coli Thioredoxin Gene Fusion Expression System and Recognition by Neutralizing Antibodies," <i>Biochemistry</i> 34:1787-1797 (1995)		
	A248	WOON <i>et al.</i> , "Construction and Characterization of a 10-Fold Genome Equivalent Rat P1-Derived Artificial Chromosome Library," <i>Genomics</i> 50:306-316 (1998)		
	A249	XIONG and PARSONS, "Induction of Apoptosis After Expression of PYK2, a Tyrosine Kinase Structurally Related to Focal Adhesion Kinase," <i>J Cell Biol</i> , 139:529-539 (1997)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/664,421
				Filing Date	09/16/2003
				First Named Inventor	Ryan BREMER
				Group Art Unit	
Examiner Name					
Sheet	26	of	26	Attorney Docket Number	039363-0703

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A250	ZHU <i>et al.</i> , "CD40 Signaling in B Cells Regulates the Expression of the Pim 1 Kinase Via the NF-κB Pathway," <i>The Journal of Immunology</i> 168:744-754 (2002)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.